Literature DB >> 12832328

Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study.

Graziella Bruno1, Franco Merletti, Annibale Biggeri, Giuseppe Bargero, Stefania Ferrero, Gianfranco Pagano, Paolo Cavallo Perin.   

Abstract

OBJECTIVE: The first sign of diabetic nephropathy is microalbuminuria, but its predictive role of progression to overt nephropathy in type 2 diabetes has not yet been clarified. The aims of this study were to assess during 7 years of follow-up the incidence rate of overt nephropathy and the predictive role of microalbuminuria and other baseline variables (blood pressure, lipids, fibrinogen, uric acid, smoking, and HbA(1c) cumulative average during follow-up). RESEARCH DESIGN AND METHODS: A prospective population-based study was performed in Casale Monferrato, Italy, including 1,253 type 2 diabetic patients recruited at baseline (1991-1992), 765 with normoalbuminuria (albumin excretion rate [AER] <20 microg/min) and 488 with microalbuminuria (AER 20-200 microg/min). All measurements were centralized. A nested case-control study within the cohort was performed, selecting four control subjects, frequency matched for age and attained individual time of follow-up with each case. Conditional regression analysis was performed to assess variables independently associated with risk of progression to overt nephropathy.
RESULTS: Of 1,253 total patients, 1,103 (88.0%) were included in the follow-up examination (median 5.33 years); their age and duration of disease at baseline were 68.4 +/- 10.5 years and 10.4 +/- 6.6 years, respectively. Cases of overt nephropathy were 202, giving an incidence rate of 37.0/1,000 person-years (95% CI 32.3-42.6). In conditional logistic regression analyses, microalbuminuria provided a 42% increased risk with respect to normoalbuminuria (95% CI 0.98-2.06), independently of duration of diabetes, hypertension, and systolic blood pressure. Other variables independently associated with progression to overt nephropathy were HbA(1c) cumulative average (P = 0.002), apolipoprotein B (P = 0.013), fibrinogen (P = 0.02), and HDL cholesterol (P = 0.03).
CONCLUSIONS: Of type 2 diabetic patients, 3.7% progress every year to overt nephropathy. Microalbuminuria is associated with a 42% increased risk of progression to overt nephropathy. Other independent predictors are HbA(1c), HDL cholesterol, apolipoprotein B, and fibrinogen.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12832328     DOI: 10.2337/diacare.26.7.2150

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  28 in total

1.  Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus.

Authors:  Stacy A Brethauer; Ali Aminian; Héctor Romero-Talamás; Esam Batayyah; Jennifer Mackey; Laurence Kennedy; Sangeeta R Kashyap; John P Kirwan; Tomasz Rogula; Matthew Kroh; Bipan Chand; Philip R Schauer
Journal:  Ann Surg       Date:  2013-10       Impact factor: 12.969

2.  Triglycerides are independently associated with albuminuria in Taiwanese Type 2 diabetic patients.

Authors:  K-J Tien; S-T Tu; H-C Chen; J-Y Hsiao; M-C Hsieh
Journal:  J Endocrinol Invest       Date:  2011-11-08       Impact factor: 4.256

3.  Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato study.

Authors:  G Bruno; F Merletti; G Bargero; G Novelli; D Melis; A Soddu; M Perotto; G Pagano; P Cavallo-Perin
Journal:  Diabetologia       Date:  2007-03-02       Impact factor: 10.122

4.  Fibrinogen and AER are major independent predictors of 11-year cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study.

Authors:  G Bruno; F Merletti; A Biggeri; G Bargero; S Ferrero; G Pagano; P Cavallo-Perin
Journal:  Diabetologia       Date:  2005-02-05       Impact factor: 10.122

Review 5.  Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?

Authors:  David J Leehey
Journal:  Kidney360       Date:  2020-02-28

6.  Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Michel Chonchol; Lorenzo Bertolini; Stefano Rodella; Luciano Zenari; Giuseppe Lippi; Massimo Franchini; Giacomo Zoppini; Michele Muggeo
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

7.  Prevalence of microalbuminuria and its risk factors in type 2 diabetic patients.

Authors:  M Afkhami-Ardekani; M Modarresi; E Amirchaghmaghi
Journal:  Indian J Nephrol       Date:  2008-07

8.  Prolonged administration enhances the renoprotective effect of pentoxifylline via anti-inflammatory activity in streptozotocin-induced diabetic nephropathy.

Authors:  Kum Hyun Han; Sang Youb Han; Han Seong Kim; Young Sun Kang; Dae Ryong Cha
Journal:  Inflammation       Date:  2010-06       Impact factor: 4.092

Review 9.  A glimpse of matrix metalloproteinases in diabetic nephropathy.

Authors:  X Xu; L Xiao; P Xiao; S Yang; G Chen; F Liu; Y S Kanwar; L Sun
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

Review 10.  Diabetic nephropathy: Is it time yet for routine kidney biopsy?

Authors:  Maria L Gonzalez Suarez; David B Thomas; Laura Barisoni; Alessia Fornoni
Journal:  World J Diabetes       Date:  2013-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.